4.7 Article

Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in Breast Cancer Brain Metastasis

Journal

MOLECULAR PHARMACEUTICS
Volume 20, Issue 12, Pages 6169-6183

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.3c00558

Keywords

breast cancer; brain metastasis; nanomedicine; hyperbranched polymer; drug delivery

Ask authors/readers for more resources

This study demonstrates the potential of a HER3-targeted hyperbranched polymer (HBP) nanomedicine for the treatment of breast cancer brain metastases. The HBP carrier can selectively deliver and release the chemotherapy drug doxorubicin (DOX) in a pH-responsive manner. The nanomedicine shows effective drug release and cytotoxicity against breast cancer cells, and in a mouse model, it inhibits tumor proliferation, reduces tumor size, and prolongs overall survival. Furthermore, the nanomedicine exhibits lower toxicity compared to free DOX.
Breast cancer brain metastases (BM) are associated with a dismal prognosis and very limited treatment options. Standard chemotherapy is challenging in BM patients because the high dosage required for an effective outcome causes unacceptable systemic toxicities, a consequence of poor brain penetration, and a short physiological half-life. Nanomedicines have the potential to circumvent off-target toxicities and factors limiting the efficacy of conventional chemotherapy. The HER3 receptor is commonly expressed in breast cancer BM. Here, we investigate the use of hyperbranched polymers (HBP) functionalized with a HER3 bispecific-antibody fragment for cancer cell-specific targeting and pH-responsive release of doxorubicin (DOX) to selectively deliver and treat BM. We demonstrated that DOX-release from the HBP carrier was controlled, gradual, and greater in endosomal acidic conditions (pH 5.5) relative to physiologic pH (pH 7.4). We showed that the HER3-targeted HBP with DOX payload was HER3-specific and induced cytotoxicity in BT474 breast cancer cells (IC50: 17.6 mu g/mL). Therapeutic testing in a BM mouse model showed that HER3-targeted HBP with DOX payload impacted tumor proliferation, reduced tumor size, and prolonged overall survival. HER3-targeted HBP level detected in ex vivo brain samples was 14-fold more than untargeted-HBP. The HBP treatments were well tolerated, with less cardiac and oocyte toxicity compared to free DOX. Taken together, our HER3-targeted HBP nanomedicine has the potential to deliver chemotherapy to BM while reducing chemotherapy-associated toxicities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available